BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses

October 27, 2016 4:10 PM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.26), $0.13 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $279.9 million versus the consensus estimate of $289.44 million.

Updated 2016 Financial Guidance

Revenue Guidance ($ in millions)

Item
Provided August 4, 2016 Updated October 27, 2016
Total BioMarin Revenues $1,100 to $1,150 Unchanged
Vimizim Net Product Revenues $340 to $360 Unchanged
Naglazyme Net Product Revenues $290 to $320 Unchanged
Kuvan Net Product Revenues $340 to $360 Unchanged

Select Income Statement Guidance ($ in millions, except percentages)

Item
Provided August 4, 2016 Updated October 27, 2016
Cost of Sales (% of Total BioMarin Revenues) 18.0% to 19.0% Unchanged
Selling, General and Admin. Expense $470 to $490 $460 to $480
Research and Development Expense $670 to $690 $650 to $670
GAAP Net Loss $(620) to $(650) $(600) to $(630)
non-GAAP Loss $(30) to $(50) $(10) to $(30)

Recent Key Program Updates

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment